The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg entacapone (ENT).

Clinical Trial Description

This study was a single-centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of 20 healthy subjects each (10 male and 10 female). The clinical part included a screening examination within 3 weeks before the first institutionalization, an ambulatory period of 11 days (from Day 1 evening to Day 11 evening), during which the subjects returned to the clinical unit every evening, followed by an institutionalization of 1.5 days (from Day 11 evening to Day 13 morning (i.e. 14 h after the third administration of levodopa/carbidopa). Then, a follow-up visit at 5 to 9 days after collection of the last PK blood sample (i.e. Day 13). The maximum total duration of the clinical study, including the 21-day screening period and the post-study follow-up, was expected to be about 39 to 43 days. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02170376
Study type	Interventional
Source	Bial - Portela C S.A.
Contact
Status	Completed
Phase	Phase 1
Start date	September 2011
Completion date	January 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02169895` - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide	Phase 1
Completed	`NCT02169479` - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa	Phase 1
Completed	`NCT02778594` - Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide	Phase 1
Completed	`NCT02274766` - Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia	Phase 3
Completed	`NCT02169453` - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa	Phase 1
Completed	`NCT04380142` - Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease	Phase 3
Withdrawn	`NCT06118294` - Efficacy of Probiotics for Parkinson Disease (PD)	N/A
Recruiting	`NCT05916157` - An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Completed	`NCT03033498` - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease	Phase 1
Completed	`NCT02169427` - An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites	Phase 1
Completed	`NCT02834507` - Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients	Phase 2
Active, not recruiting	`NCT04379050` - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease	Phase 3
Completed	`NCT02169440` - Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin	Phase 1
Completed	`NCT02202551` - Open-Label Safety Study of ADS-5102 in PD Patients With LID	Phase 3
Completed	`NCT01398748` - Intranasal Glutathione in Parkinson's Disease	Phase 1
Recruiting	`NCT06107426` - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Completed	`NCT02169466` - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide	Phase 1
Recruiting	`NCT03732898` - Coordinated Reset Deep Brain Stimulation	N/A
Completed	`NCT02799381` - A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)	Phase 3
Terminated	`NCT03829657` - Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure	Phase 3